Market Segmentation:
- By Product Type
- Ophthalmic Drugs
- Anti-VEGF Drugs
- Glaucoma Drugs
- Dry Eye Drugs
- Others (e.g., Antibiotic Drops, Corticosteroids)
- Ophthalmic Devices
- Intraocular Lenses
- Cataract Surgery Devices
- Glaucoma Devices
- Vitreoretinal Devices
- Others (e.g., Ophthalmic Lasers, Diagnostic Devices)
- Ophthalmic Drugs
- By End-User
- Hospitals
- Ophthalmology Clinics
- Ambulatory Surgical Centers
- Others (e.g., Eye Care Centers, Research Institutes)
- By Application
- Age-related Macular Degeneration
- Cataract
- Glaucoma
- Diabetic Retinopathy
- Others (e.g., Presbyopia, Dry Eye)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (e.g., Direct-to-Consumer)
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Age-related Vision Dysfunction industry is US$ 74.8 billion.
The key factors contributing significantly to the growth of the Age-related Vision Dysfunction market include the rising geriatric population, the increasing prevalence of age-related eye diseases, technological advancements in diagnostics and treatments, and growing awareness and access to eye care.
The key factors hampering the growth of the Age-related Vision Dysfunction Market include the high cost of advanced eye care treatments, lack of access to eye care in developing regions, reimbursement challenges for certain therapies, and complications associated with eye surgeries.
The key factors driving the growth of the Age-related Vision Dysfunction Market include the rising geriatric population, the increasing prevalence of age-related eye diseases, technological advancements in diagnostics and treatments, and growing awareness and access to eye care.
The leading component segment in the Age-related Vision Dysfunction Market is the ophthalmic devices segment, particularly the intraocular lenses (IOLs) subsegment, which is growing rapidly due to the increasing prevalence of cataracts and the demand for premium IOL solutions.
The major players operating in the Age-related Vision Dysfunction Market include Novartis AG, Alcon Inc., Bausch Health Companies Inc., Johnson & Johnson Vision Care, Inc., Allergan plc (Acquired by AbbVie Inc.), Bayer AG, Regeneron Pharmaceuticals, Inc., Genentech, Inc. (A Roche Group Company), Aerie Pharmaceuticals, Inc., and Santen Pharmaceutical Co., Ltd.
The Age-related Vision Dysfunction Market is expected to grow at a CAGR of 6.8% from 2023 to 2030, reaching a market size of US$ 126.6 billion by 2030.
The key drivers of the Age-related Vision Dysfunction Market include the rising geriatric population, the increasing prevalence of age-related eye diseases, technological advancements in diagnostics and treatments, growing awareness and access to eye care, and the rising demand for advanced treatment options.